본문 바로가기

모바일메뉴 열기

Overview

Overview


MitoImmune Therapeutics Inc. is a drug discovery and development biotech company that harnesses the power of mitochondria and its proprietary technology targeting mitochondria as the source for developing new potential breakthrough therapeutics. Our mission is to increase healthy lifespan by developing treatments for mitochondrial dysfunction-related necrotic and inflammatory diseases.

Founded in August 2018, the company’s lead program is based on the breakthrough scientific findings of its founder Soon Ha Kim at LG Life Sciences which was acquired by LG Chem in the end of 2017. The LG team and the collaborators from various academic and medical organizations have identified the molecular mechanism and established proof of concept data for development of new therapies. MitoImmune Therapeutics exclusively in-licensed the technology from LG Chem. Last April in 2019, the company successfully secured $10.5M through Series A funding where KB Investment, BNH Investment, KDB Industrial Bank of Korea and SL Investment participated.

MitoImmune plans to initiate domestic and global Phase 2 clinical trials for diseases of high unmet medical needs such as IPF and GvHD and to carry out full-scale activities for global licensing deals. MitoImmune is committed to adding therapeutic indications that are important for millions of patients worldwide as well as rare genetic disorders to its development pipeline to make sure the pharmaceutical potential of MIT technology is realized to the fullest extent.